ANGLE plc Completes Assay Development for AstraZeneca and Eisai Phase 2 Study
Why we think this is neutral
The RNS announcement does not contain any of the mandatory news types, such as contract news, order news, trading update, financing, or annual results. It provides an update on the successful completion of assay development projects for AstraZeneca and the results of a Phase 2 pilot study for Eisai, which are informational in nature but do not directly impact the company's financial performance or outlook.
Key Points
- Successful completion of assay development projects for AstraZeneca
- Addition of AR and DDR assays to ANGLE's menu of validated tests for pharma customers
- Successful completion of contract with Eisai, demonstrating the ability to measure HER2 CTC status dynamically over time
- Results validate ANGLE's HER2 assay for use in clinical studies to assess patient treatment response and identify likely responders to HER2-targeted therapies
Summary
ANGLE plc has successfully completed the development of Androgen Receptor (AR) and DNA Damage Response (DDR) assays for AstraZeneca, which will be added to ANGLE's menu of validated tests available to pharma customers. The company has also successfully completed its contract with Eisai, demonstrating the ability to measure HER2 CTC status dynamically over time in a Phase 2 study of a HER2-targeting antibody-drug conjugate. The results validate ANGLE's HER2 assay for use in clinical studies to assess patient treatment response and identify patients likely to respond to HER2-targeted therapies.